# Theriva Biologics, Inc.: filings

TOVX · NYSE · CIK 894158 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tovx.md) · [Financials](/companies/tovx/financials.md) · [Filings](/companies/tovx/filings.md) · [Insiders](/companies/tovx/insiders.md)

## Reports and events: 437 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (8-K 306, 4 104, 10-Q 53, 424B5 29, CORRESP 26, 424B3 25, DEF 14A 24, EFFECT 23, SC 13G/A 20, UPLOAD 20, 10-K 18, S-3 17, PRE 14A 16, SC 13G 16, DEFA14A 14, S-8 12, SC 13D/A 11, 3 10, 8-K/A 9, CT ORDER 7, D 6, S-1/A 6, ARS 4, S-1 4, S-3/A 4, DEFR14A 3, 10-K/A 2, 10-Q/A 2, POS AM 2, SC 13D 2, SCHEDULE 13G 2, SCHEDULE 13G/A 2, 424B2 1, 424B4 1, 4/A 1, FWP 1, NT 10-K 1, POS EX 1, PRER14A 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-20 | 20:15 ET | [DEF 14A](/filings/0001104659-26-117417.md) | Proxy statement, period 2026-11-18 | 0001104659-26-117417 |
| 2026-08-11 | 12:16 ET | [10-Q](/filings/0001104659-26-093786.md) | Quarterly report, period 2026-06-30 | 0001104659-26-093786 |
| 2026-08-11 | 12:10 ET | [8-K](/filings/0001104659-26-093782.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-093782 |
| 2026-08-06 | 12:10 ET | [8-K](/filings/0001104659-26-091674.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-091674 |
| 2026-08-04 | 11:20 ET | [8-K](/filings/0001104659-26-090064.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-090064 |
| 2026-07-07 | 12:10 ET | [8-K](/filings/0001104659-26-080962.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-080962 |
| 2026-06-29 | 21:28 ET | [DEF 14A](/filings/0001104659-26-078859.md) | Proxy statement, period 2026-08-03 | 0001104659-26-078859 |
| 2026-06-11 | 12:10 ET | [8-K](/filings/0001104659-26-072633.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-072633 |
| 2026-06-05 | 20:05 ET | [8-K](/filings/0001104659-26-070966.md) | 8.01 Other events | 0001104659-26-070966 |
| 2026-05-05 | 20:41 ET | [10-Q](/filings/0001104659-26-055689.md) | Quarterly report, period 2026-03-31 | 0001104659-26-055689 |
| 2026-05-05 | 20:35 ET | [8-K](/filings/0001104659-26-055679.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-055679 |
| 2026-04-30 | 20:45 ET | [DEF 14A](/filings/0001104659-26-052960.md) | Proxy statement, period 2026-06-05 | 0001104659-26-052960 |
| 2026-04-17 | 20:15 ET | [8-K](/filings/0001104659-26-044906.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-044906 |
| 2026-04-09 | 20:15 ET | [8-K](/filings/0001104659-26-041507.md) | 8.01 Other events | 0001104659-26-041507 |
| 2026-03-23 | 12:10 ET | [8-K](/filings/0001104659-26-033051.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-033051 |
| 2026-03-16 | 21:32 ET | [DEF 14A](/filings/0001104659-26-028593.md) | Proxy statement, period 2026-04-09 | 0001104659-26-028593 |
| 2026-03-12 | 12:15 ET | [10-K](/filings/0001104659-26-026767.md) | Annual report, period 2025-12-31 | 0001104659-26-026767 |
| 2026-03-12 | 12:10 ET | [8-K](/filings/0001104659-26-026765.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-026765 |
| 2026-02-18 | 13:10 ET | [8-K](/filings/0001104659-26-016792.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-016792 |
| 2026-02-12 | 13:07 ET | [8-K](/filings/0001104659-26-013907.md) | 8.01 Other events | 0001104659-26-013907 |
| 2026-01-12 | 14:11 ET | [8-K](/filings/0001104659-26-002750.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-002750 |
| 2026-01-05 | 20:30 ET | [DEF 14A](/filings/0001104659-26-000633.md) | Proxy statement, period 2026-02-11 | 0001104659-26-000633 |
| 2025-12-29 | 13:00 ET | [8-K](/filings/0001104659-25-124523.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-124523 |
| 2025-12-15 | 22:21 ET | [8-K](/filings/0001104659-25-121246.md) | 8.01 Other events | 0001104659-25-121246 |
| 2025-11-12 | 13:16 ET | [10-Q](/filings/0001104659-25-109828.md) | Quarterly report, period 2025-09-30 | 0001104659-25-109828 |
| 2025-11-12 | 13:10 ET | [8-K](/filings/0001104659-25-109821.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-109821 |
| 2025-11-10 | 21:33 ET | [DEF 14A](/filings/0001104659-25-109200.md) | Proxy statement, period 2025-12-15 | 0001104659-25-109200 |
| 2025-10-29 | 20:57 ET | [8-K](/filings/0001104659-25-103774.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-103774 |
| 2025-10-24 | 19:26 ET | [8-K](/filings/0001104659-25-102104.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-102104 |
| 2025-10-20 | 11:22 ET | [8-K](/filings/0001104659-25-100608.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-100608 |
| 2025-10-17 | 21:19 ET | [8-K](/filings/0001104659-25-100468.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-100468 |
| 2025-10-14 | 10:06 ET | [8-K](/filings/0001104659-25-098882.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-098882 |
| 2025-10-08 | 12:00 ET | [8-K](/filings/0001104659-25-097739.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-097739 |
| 2025-10-06 | 12:10 ET | [8-K](/filings/0001104659-25-096946.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-096946 |
| 2025-10-02 | 20:01 ET | [8-K](/filings/0001104659-25-096047.md) | 2.05 Exit or disposal costs | 0001104659-25-096047 |
| 2025-09-04 | 20:05 ET | [8-K](/filings/0001104659-25-087465.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-25-087465 |
| 2025-08-11 | 12:15 ET | [10-Q](/filings/0001410578-25-001654.md) | Quarterly report, period 2025-06-30 | 0001410578-25-001654 |
| 2025-08-11 | 12:10 ET | [8-K](/filings/0001104659-25-075944.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-075944 |
| 2025-07-09 | 20:50 ET | [DEF 14A](/filings/0001104659-25-066731.md) | Proxy statement, period 2025-08-29 | 0001104659-25-066731 |
| 2025-06-25 | 20:01 ET | [8-K](/filings/0001104659-25-062559.md) | 8.01 Other events | 0001104659-25-062559 |
| 2025-06-20 | 20:44 ET | [8-K](/filings/0001104659-25-061203.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-061203 |
| 2025-06-02 | 11:00 ET | [8-K](/filings/0001104659-25-055181.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-055181 |
| 2025-05-14 | 12:15 ET | [10-Q](/filings/0001410578-25-001242.md) | Quarterly report, period 2025-03-31 | 0001410578-25-001242 |
| 2025-05-14 | 12:10 ET | [8-K](/filings/0001104659-25-048183.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-048183 |
| 2025-05-08 | 20:30 ET | [8-K](/filings/0001104659-25-046170.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-046170 |
| 2025-05-07 | 11:10 ET | [8-K](/filings/0001104659-25-045309.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-045309 |
| 2025-03-31 | 12:31 ET | [8-K](/filings/0001104659-25-029654.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-029654 |
| 2025-03-21 | 20:31 ET | [S-1/A](/filings/0001104659-25-026682.md) | Registration statement, amended | 0001104659-25-026682 |
| 2025-03-06 | 21:24 ET | [10-K](/filings/0001410578-25-000285.md) | Annual report, period 2024-12-31 | 0001410578-25-000285 |
| 2025-03-06 | 21:17 ET | [8-K](/filings/0001104659-25-021379.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-021379 |

Page 1 of 9. [Older](/companies/tovx/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 14:59 ET. No prices; not investment advice.